Please use this identifier to cite or link to this item: http://dx.doi.org/10.25673/92704
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVasapolli, Riccardo-
dc.contributor.authorSchulz, Christian-
dc.contributor.authorSchweden, Melanie-
dc.contributor.authorCasèn, Christina-
dc.contributor.authorKirubakaran, Graceline Tina-
dc.contributor.authorKirste, Katrine Hånes-
dc.contributor.authorMacke, Lukas-
dc.contributor.authorLink, Alexander-
dc.contributor.authorSchütte, Kerstin-
dc.contributor.authorMalfertheiner, Peter-
dc.date.accessioned2022-11-11T09:29:30Z-
dc.date.available2022-11-11T09:29:30Z-
dc.date.issued2021-
dc.date.submitted2021-
dc.identifier.urihttps://opendata.uni-halle.de//handle/1981185920/94660-
dc.identifier.urihttp://dx.doi.org/10.25673/92704-
dc.description.abstractBackground: Distinct faecal microbiota profiles are reported to be associated with various subtypes of IBS. Circulating antibodies to cytolethal distending toxin B (CdtB) and vinculin are proposed as biomarkers to identify post-infectious IBS. The aim of our study was to analyse serum levels of anti-CdtB and anti-vinculin antibodies in patients with different functional gastrointestinal disorders (FGID) and their correlation with the composition of faecal microbiome. Methods: The study cohort comprised 65 prospectively recruited individuals: 15 with diarrhoea-type- IBS (IBS-D), 13 with constipation-type- IBS (IBS-C), 15 with functional dyspepsia (FD) and 22 healthy controls. FGID subgroups were defined according to Rome III criteria. Serum levels of anti-CdtB and anti-vinculin antibodies were measured by ELISA. Faecal microbiome composition analysis and assessment of dysbiosis were performed by GA-map ® Dysbiosis Test. Results: Positivity rate either for anti-CdtB or anti-vinculin antibodies was higher in the IBS-C group (76.9%) compared to IBS-D (40.0%), FD (60%) and healthy (63.6%) groups. Dysbiosis was more frequent in subjects positive for anti-CdtB antibodies and in IBS-C patients, who showed an increased amount of opportunistic/pro-inflammatory bacteria and reduced gut protective bacteria. IBS-C patients showed a high inter-individual variation of bacterial communities compared to other FGID subgroups and healthy individuals, whereas microbial profiles of patients with IBS-D and FD were overlapping with those of healthy controls. No bacteria markers showed significant differences between FGID subgroups and healthy controls. Conclusion: Neither anti-CdtB/ anti-vinculin antibodies nor faecal microbial profiles allowed to discriminate between specific FGID subgroups. Dysbiosis was more frequent in patients presenting with anti-CdtB antibodies and in IBS-C patients.eng
dc.description.sponsorshipProjekt DEAL 2021-
dc.language.isoeng-
dc.relation.ispartof10.1111/(ISSN)1365-2362-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/-
dc.subjectCytolethal distending toxin/ vinculineng
dc.subjectDysbiosiseng
dc.subjectFaecal microbiotaeng
dc.subjectFunctional dyspepsiaeng
dc.subjectIrritable bowel syndromeeng
dc.subject.ddc610.72-
dc.titleGut microbiota profiles and the role of anti-CdtB and anti-vinculin antibodies in patients with functional gastrointestinal disorders (FGID)eng
dc.typeArticle-
dc.identifier.urnurn:nbn:de:gbv:ma9:1-1981185920-946602-
local.versionTypepublishedVersion-
local.bibliographicCitation.journaltitleEuropean journal of clinical investigation-
local.bibliographicCitation.volume51-
local.bibliographicCitation.issue12-
local.bibliographicCitation.pagestart1-
local.bibliographicCitation.pageend10-
local.bibliographicCitation.publishernameWiley-Blackwell-
local.bibliographicCitation.publisherplaceOxford [u.a.]-
local.bibliographicCitation.doi10.1111/eci.13666-
local.openaccesstrue-
dc.identifier.ppn1771062150-
local.bibliographicCitation.year2021-
cbs.sru.importDate2022-11-11T09:23:35Z-
local.bibliographicCitationEnthalten in European journal of clinical investigation - Oxford [u.a.] : Wiley-Blackwell, 1970-
local.accessrights.dnbfree-
Appears in Collections:Medizinische Fakultät (OA)

Files in This Item:
File Description SizeFormat 
Vasapolli et al._Gut microbiota_2021.pdfZweitveröffentlichung410.38 kBAdobe PDFThumbnail
View/Open